Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1131-1136

  Singh, Amareshwar T K ^a   Evens, Andrew M ^a   Prachand, Sheila N ^a   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Lymphoma; Motexafin gadolinium; p53; Reactive oxygen species

Indexed keywords

ASCORBIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOPHILIN A; GADOLINIUM TEXAPHYRIN; GLUTATHIONE PEROXIDASE 1; NUTLIN 3; OXIDIZING AGENT; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; ZINC;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL; LYMPHOMA CELL LINE; OUTCOME ASSESSMENT; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION;

APOPTOSIS; ASCORBIC ACID; BURKITT LYMPHOMA; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; IMIDAZOLES; LEUPEPTINS; LYMPHOMA, FOLLICULAR; METALLOPORPHYRINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53; ZINC;

EID: 77953793967     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Knoops L and de Jong D: The role of the p53 pathway in the treatment of follicular lymphoma. Cell Cycle 7: 436-439, 2009.
2. Hecht JL and Aster JC: Molecular biology of Burkitt's lymphoma. J Clin Oncol 18: 3707-3721, 2000.
3. Zhang XP, Liu F, Cheng Z and Wang W: Cell fate decision mediated by p53 pulses. Proc Natl Acad Sci USA 106: 12245-12250, 2009.
4. Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723, 2009.
5. Brosch R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713, 2009.
6. Hainaut P and Wiman KG: 30 Y and a long way into p53 research. Lancet Oncol 10: 913-919, 2009.
7. Tomko RJ Jr, Bansal P and Lazo JS: Airing out an antioxidant role for the tumor suppressor p53. Mol Interv 6: 23-25, 2006.
8. Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR: The p53 Network. J Biol Chem 273: 1-4, 1998.
9. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306-1313, 2005.
10. Magda D and Miller RA: Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 16: 466-476, 2006.
11. Evens AM, Balasubramanian L and Gordon LI: Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. Curr Treat Options Oncol 6: 289-296, 2005. (Pubitemid 41223383)
12. Magda D, Gerasimchuk N, Lecane P, Miller RA, Biaglow JE and Sessler JL: Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 22: 2730-2731, 2002.
13. Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB and Gordon LI: Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105: 1265-1273, 2005.
14. Mahabir S, Spitz MR, Barrera SL, Beaver SH, Etzel C, and Forman MR: Dietary zinc, copper and selenium, and risk of lung cancer. Int J Cancer 120: 1108-1115, 2007.
15. Singh ATK, Anderson RJ, Sankar N, Beckstead J, Ryan RO and Gordon LI: All trans retinoic acid nanodisks stimulate reactive oxygen species (ROS)-mediated apoptosis in mantle cell lymphoma (MCL) cell lines. Mantle Cell Lymphoma Consortium Initiative Meeting. Atlanta, Georgia, 2009.
16. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
17. Bao-Lei T, Zhu-Zhong M, Yi S, Jun-Jie Q, Yan D, Hua L, Bin L, Guo-Wei Z and Zhi-Xian S: Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7. J Cell Biochem 97: 561-571, 2006.
18. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
19. Cerullo N, Bufalino D and Daquino G: Progress in the use of gadolinium for NCT. Appl Radiat Isot 67: 157-160, 2009.
20. Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ and Medeiros LJ: The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wildtype or mutated p53. Leukemia 23: 2290-2299, 2009.
21. Kopnin PB, Agapova LS, Kopnin BP and Chumakov PM: Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 67: 4671-4678, 2007.
22. Tan M, Li S, Swaroop M, Guan K, Oberley LW and Sun Y: Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 274: 12061-12066, 1999.
23. Ding WX, Ni HM, Chen X, Yu J, Zhang L and Yin XM: A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 6: 1062-1069, 2007.
24. Carew JS, Nawrocki ST and Cleveland JL: Modulating autophagy for therapeutic benefit. Autophagy 3: 464-467, 2007.
25. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besançon F, Bauvy C and Codogno P: Regulation of autophagy by NFkappaB transcription factor and reactive oxygen species. Autophagy 3: 390-392, 2007. (Pubitemid 46986353)
26. Michael D and Oren M: The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13: 49-58, 2003.
27. Vassilev LT: Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65: 1918-1924, 2005.
28. Hainaut P and Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3: 611-623, 2001. (Pubitemid 32785984)